Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06544655 · ClinicalTrials.gov registry record · Phase 1

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
213
Enrollment target
11
Study locations

NCT06544655 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 213 participants, roughly in line with the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target. The trial reports 11 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06544655, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
213 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG Capecitabine
  • DRUG Fluorouracil
  • DRUG Oxaliplatin
  • BIOLOGICAL Nivolumab
  • DRUG BMS-986484

Study Locations (11)

Arizona

  • University of Arizona Cancer Center - Tucson

California

  • USC/Norris Comprehensive Cancer Center - Los Angeles

Michigan

  • START Midwest - Grand Rapids

South Dakota

  • Sanford Cancer Center - Sioux Falls

Texas

  • NEXT Oncology - San Antonio

New South Wales

  • St Vincent's Hospital - Darlinghurst

South Australia

  • Lyell McEwin Hospital - Elizabeth Vale

Ontario

  • Princess Margaret Cancer Centre - Toronto

Trial Details

FieldValue
Enrollment Target 213 participants
Start Date 2024-10-10
Est. Completion 2027-10-14
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06544655

The ClinicalTrials.gov registry entry for NCT06544655 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.

NCT06544655 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Arizona, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT06544655 about?

NCT06544655 is a clinical study titled "A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors". The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic du...

What is the current status of trial NCT06544655?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 213 participants. The study started on 2024-10-10. Estimated completion is 2027-10-14.

What conditions does trial NCT06544655 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06544655?

The interventions under investigation include: Capecitabine (DRUG), Fluorouracil (DRUG), Oxaliplatin (DRUG), Nivolumab (BIOLOGICAL), BMS-986484 (DRUG).

Who is sponsoring clinical trial NCT06544655?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06544655 being conducted?

This trial has 11 study locations across Arizona, California, Michigan, South Dakota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.